What are the recent financial highlights of GRANULES INDIA LIMITED?

GRANULES INDIA LIMITED recently reported a total revenue of ₹4,459.96 Cr and a net profit margin of 10.74%. These metrics reflect the company’s consistent financial performance.

What is the dividend yield of GRANULES INDIA LIMITED?

GRANULES INDIA LIMITED offers a dividend yield of 0.33%, with a dividend rate of ₹1.5 per share.

What are the key financial metrics of GRANULES INDIA LIMITED?

Key financial metrics include a trailing P/E ratio of 21.971617, forward P/E of 17.0242, book value of ₹141.342, price-to-book ratio of 3.067029, and a market capitalization of ₹105.25 billion.

What does GRANULES INDIA LIMITED do?

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.

Loading...

₹ 0 0.00%

Loading... BSE: Loding... NSE: Granules

About

Loading... ^[1]

Website BSE NSE

Market Cap ₹ 0 Cr.
Current Price ₹ 0
High / Low ₹ 0 / 0
Stock P/E
Dividend Yield 0 %
ROE 0 %
EPS 0
P/B Ratio 0
Net Profit Margin 0 %
Debt to Equity 0
ROCE 0 %
Interest Coverage 0 %

Stock News - Granules

Latest updates related to Granules

Sr No.	Title	Sentiment
1	USFDA pulls up Granules India for lapses in maintaining storage facilities, equipment at Telangana plant The Economic Times	🔄
2	GRANULES Outlook for the Week (March 10, 2025 – March 14, 2025) EquityPandit	🔄
3	Granules India gets US food regulator's warning for lapses at Telangana plant Hindustan Times	🔄
4	Granules India shares tumble almost 8% after USFDA issues warning letter for its Gagillapur facility Mint	🔄
5	US FDA issues warning letter to Granules India's Gagillapur facility Moneycontrol	🔄
6	U.S. FDA issues warning letter to Granules unit in Hyderabad The Hindu	🔄
7	USFDA issues warning letter for Granules India Gagillapur plant, new product approvals to take a hit The Times of India	🔄
8	Granules India Ltd Falls 3.02% Business Standard	🔄
9	Explained — Why Granules India shares fell on Wednesday CNBCTV18	🔄
10	India’s Granules makes $22M play for Senn Chemicals to enter peptides CDMO business FiercePharma	🔄

Peer Comparison

Macro Industry: Loading.. | Sector: Loading.. | Industry: Loading.. | Basic Industry: Loading..

Loading peers table...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Loading data...

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Loading Profit & Loss data...

Compounded Sales Growth
10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth
10 Years:
5 Years:
3 Years:
TTM:

Stock Price CAGR
10 Years:
5 Years:
3 Years:
1 Year:

Return on Equity
10 Years:
5 Years:
3 Years:
Last Year:

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Shareholding Pattern

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Delivery Data

Insider Data

Technical Data

Static Application Security Testing

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls

Explore More Stocks

INDORAMA AARTIPHARM CARYSIL NORTHARC CYBERMEDIA ICICIGI PATELENG CARTRADE BSE MODTHREAD